Landiolol: An Ultra-Short-Acting β-Blocker
Shiavax J Rao1, Arjun Kanwal2, Amreen Kanwal3
1From the Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD.
Cardiology in Review
|May 15, 2023
Summary
Landiolol, a highly cardio-selective beta-blocker, shows promise in managing tachyarrhythmias and preventing postoperative atrial fibrillation. Further research is encouraged for its novel clinical applications.
Area of Science:
- Pharmacology
- Cardiology
- Critical Care Medicine
Background:
- Landiolol is an ultra-short-acting, highly cardio-selective beta-blocker.
- It is approved in Japan and the EU for treating tachyarrhythmias.
- Landiolol exhibits high beta-1 selectivity, leading to potent chronotropic and less hypotensive effects compared to other beta-blockers.
Purpose of the Study:
- To review the potential clinical applications of landiolol.
- To explore its role in managing tachyarrhythmias and preventing postoperative atrial fibrillation.
- To assess its utility in myocardial salvage and sepsis-related conditions.
Main Methods:
- Review of recent randomized controlled trials.
- Analysis of landiolol's pharmacological properties and clinical outcomes.
- Evaluation of its efficacy in various surgical and critical care settings.
Main Results:
- Low-dose landiolol may prevent and manage postoperative atrial fibrillation after various surgeries.
- Potential utility for myocardial salvage and preventing myocardial infarction post-PCI.
- Therapeutic effect for rate control in sepsis-related tachyarrhythmias.
Conclusions:
- Landiolol demonstrates significant potential in managing diverse cardiovascular conditions.
- Ongoing research and larger studies are warranted to explore its full clinical utility.
- The drug shows promise for novel applications beyond its current approvals.
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
530
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
530
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
784
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
784
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
900
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
900
01:28Antihypertensive Drugs: Types of β-Blockers
773
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
773
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.1K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.1K
01:17Antihypertensive Drugs: Action of β1 Blockers
494
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
494